Pulmonary or Respiratory Drug Delivery Market Report 2026

The pulmonary or respiratory drug delivery market size has grown strongly in recent years. It will grow from $75.67 billion in 2025 to $82.23 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising asthma and copd prevalence, widespread inhaler adoption, growth in respiratory hospitals, improved aerosol technologies, expansion of homecare treatments.

The pulmonary or respiratory drug delivery market size is expected to see strong growth in the next few years. It will grow to $114.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to aging population, rising air pollution exposure, growth in digital inhalers, expansion of homecare settings, increasing chronic respiratory conditions. Major trends in the forecast period include rising adoption of inhalation-based drug delivery, increasing demand for home-based respiratory therapies, growing use of dry powder and metered dose inhalers, expansion of chronic respiratory disease management, increased focus on patient-friendly delivery devices.

The rising prevalence of pneumonia is expected to drive the growth of the pulmonary or respiratory drug delivery market in the coming years. Pneumonia is a lung infection that causes inflammation of the air sacs, which may fill with fluid or pus, resulting in symptoms such as cough, fever, and difficulty breathing. Factors contributing to the increasing prevalence of pneumonia include aging populations, weakened immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery assists pneumonia patients by directly targeting the lungs with medications, including antibiotics, bronchodilators, or anti-inflammatory agents, allowing for faster and more effective treatment to relieve symptoms, reduce inflammation, eliminate infections, and improve respiratory function, ultimately supporting recovery and preventing complications. For example, in December 2024, Clinical Trials Arena, a UK-based clinical research news platform, reported that hospital admissions for Mycoplasma pneumoniae rose by 461% from October 2023 to February 2024, increasing from 110 to 617 admissions, with 20.2% of pneumonia cases detected in children aged 0 to 4 years, 25.4% in children aged 5 to 9 years, and 17.5% in children aged 10 to 14 years, accounting for 410 of the 650 cases reported. Consequently, the growing prevalence of pneumonia fuels the pulmonary or respiratory drug delivery market.

Major companies operating in the pulmonary or respiratory drug delivery market are concentrating on technological innovations such as sophisticated drug delivery systems that improve treatment effectiveness and patient adherence. Sophisticated drug delivery systems are advanced technologies that facilitate targeted delivery and controlled release of therapeutic agents, enhancing drug performance and patient outcomes. For example, in July 2023, Viatris Inc., a US-based healthcare company that produces generic and branded medications, and Kindeva Drug Delivery L.P., a US-based firm specializing in drug delivery, launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol approved by the Food and Drug Administration, a US government agency. This is the first generic version of AstraZeneca's Symbicort and a metered-dose inhaler combining budesonide and formoterol for the treatment of asthma and chronic obstructive pulmonary disease. It is offered in two strengths of 80 micrograms and 160 micrograms with 4.5 micrograms of formoterol.

In January 2025, Molex LLC, a US-based electronic solutions provider and parent company of Phillips-Medisize, acquired Vectura Group Ltd. for an undisclosed amount. Through this acquisition, Molex intends to strengthen Phillips-Medisize’s pulmonary and respiratory drug delivery capabilities by incorporating Vectura’s advanced inhalation device technologies, supporting the development of next-generation inhalation therapies and broadening its global product portfolio. Vectura Group Ltd. is a UK-based provider of inhalation drug delivery systems with a strong history of innovation in respiratory therapy devices.

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc.

North America was the largest region in the pulmonary or respiratory drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmonary or respiratory drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pulmonary drug delivery market by increasing the cost of imported devices, propellant canisters, and formulation components used in inhalation therapies. The impact is most visible in inhaler and nebulizer segments, where device precision and component availability are critical. Regions such as Asia Pacific and Europe have experienced higher input costs due to reliance on cross border medical device supply chains. Rising tariff related expenses have influenced product pricing, procurement decisions, and launch timelines. However, tariffs have supported local device manufacturing, encouraged innovation in inhalation technologies, and strengthened regional production ecosystems over the long term.

The pulmonary or respiratory drug delivery market research report is one of a series of new reports that provides pulmonary or respiratory drug delivery market statistics, including pulmonary or respiratory drug delivery industry global market size, regional shares, competitors with a pulmonary or respiratory drug delivery market share, detailed pulmonary or respiratory drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary or respiratory drug delivery industry. This pulmonary or respiratory drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmonary or respiratory drug delivery involves administering medication directly into the lungs to ensure rapid absorption, focused treatment, and minimized systemic side effects, providing both local and systemic therapeutic benefits.

The primary categories of pulmonary or respiratory drug delivery are based on formulation type and device type. Formulation type refers to the method of preparing drugs to ensure effective administration, accurate dosing, and proper absorption in the body. The different canister types include plain canisters and coated canisters. These are utilized for various applications such as chronic obstructive pulmonary disease, asthma, cystic fibrosis, and other conditions. They are also employed by different end-users, including hospitals, clinics, and home care settings.

The pulmonary or respiratory drug delivery market consists of sales of metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, aerosol formulations, and smart inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.